Shamburg News · 8-K filed Nov 16, 2026, 8:10 AM EST

ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update

ALXO · ALX ONCOLOGY HOLDINGS INC

  • Earnings
  • Materiality: high

ALX Oncology Holdings Inc. reported a GAAP net loss of $21.8 million, or $0.15 per basic and diluted share, for the third quarter ended September 30, 2026, compared with a net loss of $22.1 million, or $0.41 per share, in the prior-year quarter. R&D expenses were $17.5 million and G&A expenses were $5.5 million for the quarter. Cash, cash equivalents and investments were $147.2 million as of September 30, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-462188.

Written from the filing by Shamburg Markets. Figures are as reported by the company.